BALYASNY ASSET MANAGEMENT L.P. 13D and 13G filings for SAB Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-14 06:08 am Purchase | 2026-06-30 | 13G | SAB BIOTHERAPEUTICS INC NE SABS | BALYASNY ASSET MANAGEMENT L.P. | 7,225,439 9.450% | 2,135,500 (+41.96%) | Filing |
| 2026-05-15 06:28 am Purchase | 2026-03-31 | 13G | SAB BIOTHERAPEUTICS INC NE SABS | BALYASNY ASSET MANAGEMENT L.P. | 5,089,939 9.990% | 5,089,939 (New Position) | Filing |